198 related articles for article (PubMed ID: 37063293)
1. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
Fennell EMJ; Aponte-Collazo LJ; Pathmasiri W; Rushing BR; Barker NK; Partridge MC; Li YY; White CA; Greer YE; Herring LE; Lipkowitz S; Sumner SCJ; Iwanowicz EJ; Graves LM
Front Pharmacol; 2023; 14():1136317. PubMed ID: 37063293
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
[TBL] [Abstract][Full Text] [Related]
3. Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP.
Fennell EMJ; Aponte-Collazo LJ; Wynn JD; Drizyte-Miller K; Leung E; Greer YE; Graves PR; Iwanowicz AA; Ashamalla H; Holmuhamedov E; Lang H; Karanewsky DS; Der CJ; Houry WA; Lipkowitz S; Iwanowicz EJ; Graves LM
Pharmacol Res Perspect; 2022 Aug; 10(4):e00993. PubMed ID: 35929764
[TBL] [Abstract][Full Text] [Related]
4. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.
Lim B; Peterson CB; Davis A; Cho E; Pearson T; Liu H; Hwang M; Ueno NT; Lee J
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680527
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
Greer YE; Hernandez L; Fennell EMJ; Kundu M; Voeller D; Chari R; Gilbert SF; Gilbert TSK; Ratnayake S; Tang B; Hafner M; Chen Q; Meerzaman D; Iwanowicz E; Annunziata CM; Graves LM; Lipkowitz S
Cancer Res Commun; 2022 Oct; 2(10):1144-1161. PubMed ID: 36388465
[TBL] [Abstract][Full Text] [Related]
6. ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.
Mishukov A; Odinokova I; Mndlyan E; Kobyakova M; Abdullaev S; Zhalimov V; Glukhova X; Galat V; Galat Y; Senotov A; Fadeev R; Artykov A; Gasparian ME; Solovieva M; Beletsky I; Holmuhamedov E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555190
[TBL] [Abstract][Full Text] [Related]
7. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
8. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
Zhang J; Luo B; Sui J; Qiu Z; Huang J; Yang T; Luo Y
Biochem Pharmacol; 2022 Oct; 204():115232. PubMed ID: 36030831
[TBL] [Abstract][Full Text] [Related]
9. Caseinolytic protease P (CLPP) activated by ONC201 inhibits proliferation and promotes apoptosis in human epithelial ovarian cancer cells by inducing mitochondrial dysfunction.
Kou X; Ding H; Li L; Chao H
Ann Transl Med; 2021 Sep; 9(18):1463. PubMed ID: 34734015
[TBL] [Abstract][Full Text] [Related]
10. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
[TBL] [Abstract][Full Text] [Related]
11. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
12. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
[TBL] [Abstract][Full Text] [Related]
13. ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN.
Wu JC; Huang CC; Wang PW; Chen TY; Hsu WM; Chuang JH; Chuang HC
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675163
[TBL] [Abstract][Full Text] [Related]
14. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
Zhang Y; Tapinos N; Lulla R; El-Deiry WS
Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
[TBL] [Abstract][Full Text] [Related]
15. Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.
Fan Y; Wang J; Fang Z; Pierce SR; West L; Staley A; Tucker K; Yin Y; Sun W; Kong W; Prabhu V; Allen JE; Zhou C; Bae-Jump VL
Front Oncol; 2022; 12():789450. PubMed ID: 35372029
[TBL] [Abstract][Full Text] [Related]
16. Potent ClpP agonists with anticancer properties bind with improved structural complementarity and alter the mitochondrial N-terminome.
Mabanglo MF; Wong KS; Barghash MM; Leung E; Chuang SHW; Ardalan A; Majaesic EM; Wong CJ; Zhang S; Lang H; Karanewsky DS; Iwanowicz AA; Graves LM; Iwanowicz EJ; Gingras AC; Houry WA
Structure; 2023 Feb; 31(2):185-200.e10. PubMed ID: 36586405
[TBL] [Abstract][Full Text] [Related]
17. ONC201 kills breast cancer cells
Greer YE; Porat-Shliom N; Nagashima K; Stuelten C; Crooks D; Koparde VN; Gilbert SF; Islam C; Ubaldini A; Ji Y; Gattinoni L; Soheilian F; Wang X; Hafner M; Shetty J; Tran B; Jailwala P; Cam M; Lang M; Voeller D; Reinhold WC; Rajapakse V; Pommier Y; Weigert R; Linehan WM; Lipkowitz S
Oncotarget; 2018 Apr; 9(26):18454-18479. PubMed ID: 29719618
[TBL] [Abstract][Full Text] [Related]
18. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
Jacques S; van der Sloot AM; C Huard C; Coulombe-Huntington J; Tsao S; Tollis S; Bertomeu T; Culp EJ; Pallant D; Cook MA; Bonneil E; Thibault P; Wright GD; Tyers M
Genetics; 2020 Apr; 214(4):1103-1120. PubMed ID: 32094149
[TBL] [Abstract][Full Text] [Related]
19. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
Ralff MD; Jhaveri A; Ray JE; Zhou L; Lev A; Campbell KS; Dicker DT; Ross EA; El-Deiry WS
Oncotarget; 2020 Oct; 11(42):3753-3769. PubMed ID: 33144917
[TBL] [Abstract][Full Text] [Related]
20. ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells.
Cao J; Cao F; Wang C; Jiao Z; You Y; Wang X; Zhao W
Neoplasia; 2024 Jun; 55():101015. PubMed ID: 38944913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
